Mission Creek Capital Partners Inc. Buys 43 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mission Creek Capital Partners Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,456 shares of the medical research company’s stock after purchasing an additional 43 shares during the quarter. Mission Creek Capital Partners Inc.’s holdings in Thermo Fisher Scientific were worth $1,798,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TMO. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $30,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.6 %

Shares of NYSE:TMO opened at $424.02 on Friday. The stock’s fifty day moving average price is $487.28 and its 200-day moving average price is $527.17. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $160.06 billion, a P/E ratio of 25.65, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday. UBS Group reduced their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $616.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.